Johnson & Johnson (JNJ) boosted its sales and profit outlook for the year after reporting second-quarter financial results that beat Wall Street expectations, aided by growth in its pharmaceuticals business.
The company raised its full-year sales guidance of $71.5 billion to $72.2 billion, up from the sweetened forecast of $71.2 billion to $71.9 billion the company issued in April. It also increased its adjusted 2016 earnings guidance to a range of $6.63 to $6.73 per share, up from $6.53 to $6.68.
18:05 DP World, Quebec's Caisse to create C$5 billion investment vehicle12
23:15 Howard Schultz stepping down as Starbucks CEO; current COO to replace him14
21:05 Starbucks Chief Howard Schultz to Step Down Next Year11
15:54 Johnson & Johnson raising takeover offer for Actelionl: source15